Clinical trial • Phase I • Haematology
TU7710 for Hemophilia A | Hemophilia B
Phase I trial of TU7710 for Hemophilia A | Hemophilia B. None/Not specified-controlled. 21 participants.
Overview
- Trial Therapeutic Area
- Haematology
- Trial Disease
- Hemophilia A | Hemophilia B
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 19-03-2024
- First CTIS Authorization Date
- 08-07-2024
Trial design
None/Not specified-controlled Phase I trial across 6 sites in Italy, Spain, Bulgaria and others.
- Comparator
- None/Not specified
- Target Sample Size
- 21
Eligibility
Recruits 21 Vulnerable population not selected; no special consent or assent handling described..
- Vulnerable Population
- Vulnerable population not selected; no special consent or assent handling described.
Recruitment
- Planned Sample Size
- 21
- Recruitment Window Months
- 30
Geography
- Total Number Of Sites
- 6
- Total Number Of Participants
- 21
Italy
- Earliest CTIS Part Ii Submission Date
- 03-05-2024
- Latest Decision Or Authorization Date
- 12-05-2026
- Processing Time Days
- 739
- Number Of Sites
- 1
- Number Of Participants
- 8
Sites
- Site Name
- Careggi University Hospital
- Department Name
- Oncologia
- Principal Investigator Name
- Giancarlo Castaman
- Principal Investigator Email
- castaman@aou-careggi.toscana.it
- Contact Person Name
- Giancarlo Castaman
- Contact Person Email
- castaman@aou-careggi.toscana.it
Spain
- Earliest CTIS Part Ii Submission Date
- 28-06-2024
- Latest Decision Or Authorization Date
- 12-05-2026
- Processing Time Days
- 683
- Number Of Sites
- 3
- Number Of Participants
- 8
Sites
- Site Name
- Hospital Universitario Regional De Malaga
- Department Name
- Hematology
- Principal Investigator Name
- Francisco Javier Lopez Jaime
- Principal Investigator Email
- franlopezjaime@gmail.com
- Contact Person Name
- Francisco Javier Lopez Jaime
- Contact Person Email
- franlopezjaime@gmail.com
- Site Name
- Hospital Universitario Y Politecnico La Fe
- Department Name
- Hematology
- Principal Investigator Name
- Ana Cid Haro
- Principal Investigator Email
- cid_ana@gva.es
- Contact Person Name
- Ana Cid Haro
- Contact Person Email
- cid_ana@gva.es
- Site Name
- University Hospital Virgen Del Rocio S.L.
- Department Name
- Hematology
- Principal Investigator Name
- Ramiro Nuñez Vazquez
- Principal Investigator Email
- ramirojosenv@gmail.com
- Contact Person Name
- Ramiro Nuñez Vazquez
- Contact Person Email
- ramirojosenv@gmail.com
Bulgaria
- Earliest CTIS Part Ii Submission Date
- 03-03-2025
- Latest Decision Or Authorization Date
- 12-05-2026
- Processing Time Days
- 435
- Number Of Sites
- 1
- Number Of Participants
- 3
Sites
- Site Name
- Specialized Hospital For Active Treatment Of Hematological Diseases EAD
- Department Name
- III Department of Clinical Hematology
- Principal Investigator Name
- Toshko Lissitchkov
- Principal Investigator Email
- t_lissitchkov@yahoo.com
- Contact Person Name
- Toshko Lissitchkov
- Contact Person Email
- t_lissitchkov@yahoo.com
Romania
- Earliest CTIS Part Ii Submission Date
- 21-11-2024
- Latest Decision Or Authorization Date
- 21-07-2025
- Processing Time Days
- 242
- Number Of Sites
- 1
- Number Of Participants
- 2
Sites
- Site Name
- Institute Of Oncology Prof. Dr. Ion Chiricuta Cluj-Napoca
- Department Name
- Hematologie
- Principal Investigator Name
- Criprian Tomuleasa
- Principal Investigator Email
- office@iocn.ro
- Contact Person Name
- Criprian Tomuleasa
- Contact Person Email
- office@iocn.ro
Sponsor
Primary sponsor
- Full Name
- Tiumbio Co. Ltd.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Korea, Republic of
Investigational products
- Investigational Product Name
- TU7710
Related trials
Other published trials that may interest you.
- FITUSIRAN for Hemophilia A | Hemophilia B
- (S)-4,5-DIHYDRO-2-[2-HYDROXY-4-(3,6-DIOXAHEPTYLOXY)PHENYL]-4-METHYL-4-THIAZOLECARBOXYLIC ACID for Transfusion-dependent alpha thalassemia | Transfusion-dependent beta thalassemia | Low-risk myelodysplastic syndromes
- Luspatercept for Myelofibrosis | Anemia associated with myeloproliferative neoplasm-associated myelofibrosis
- GIVINOSTAT for Chronic myeloproliferative neoplasm
- GOLCADOMIDE for Follicular lymphoma (advanced stage)